Digital Pathology Market: Integrating Telepathology Into Routine Practice

The global digital pathology market, valued at $1.03 billion in 2023, is projected to expand at a steady 8% annual rate from 2024 to 2030. This growth is primarily driven by several factors: the increasing prevalence of cancer, the need to improve workflow efficiency, and the growing demand for faster diagnostic tools. Furthermore, rising investments in healthcare, coupled with strategic initiatives from key market players, including new product launches, expanding telepathology adoption, and a focus on drug discovery and precision medicine, are accelerating market growth.

The increasing adoption of healthcare IT solutions is fueling the demand for digital pathology solutions. Organizations are increasingly implementing 1 these solutions to reduce costs, streamline processes, address resource constraints, and facilitate efficient content sharing. The growing need for collaborations and the expanding use of digital documentation across various scientific fields further drive demand. Additionally, factors such as the heightened adoption of digital pathology to enhance laboratory efficiency, the surge in teleconsultations, and increased applications in companion diagnostics and drug discovery are expected to contribute to the market's growth.

Gather more insights about the market drivers, restrains and growth of the Digital Pathology Market

Product Segmentation Insights 

The device segment, comprising slide management systems and scanners, held the largest market share of 51.72% in 2023. This segment is poised for significant growth in the coming years due to the increasing adoption of digital pathology in academic research. The enhanced resolution offered by these devices is a key driver behind this trend.

A notable example is the VENTANA DP 600 slide scanner, introduced by F. Hoffmann-La Roche Ltd. in June 2022. This cutting-edge scanner generates high-resolution digital images of tissue samples, aiding in cancer diagnosis and treatment planning.

Software Segment's Rapid Expansion

The software segment is projected to experience the fastest growth rate from 2024 to 2030. The rising incidence of cancer and the focus of key industry players on developing innovative digital pathology systems are driving this expansion.

Xybion Corp.'s Pristima XD Digital Pathology is a prime example of this trend. Launched in August 2021, this software enhances lab throughput and streamlines workflows. Similarly, F. Hoffmann-La Roche Ltd.'s uPath enterprise software, introduced in January 2019, improves performance, speed, and overall usability in digital pathology.

Conclusion

The digital pathology market is characterized by the dominance of the device segment, driven by advancements in slide management systems and scanners. However, the software segment is rapidly gaining traction due to its crucial role in enhancing efficiency and improving diagnostic outcomes.

Order a free sample PDF of the Digital Pathology Market Intelligence Study, published by Grand View Research.